자궁내 피임기구(IUD) 시장 : 시장 인사이트, 경쟁 환경 및 시장 예측([-2030년)

Intrauterine Devices Market By Type (Hormonal Intrauterine And Copper Intrauterine), By End-User Type (Hospitals, Gynaecology Clinics And Community Health Care Centres), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increase in awaremness in family planning and high rates of unintended pregnancies.

Global Intrauterine Devices Market was valued at USD 4.85 billion in 2023, growing at a CAGR of 5.81% during the forecast period from 2024 to 2030 to reach USD 6.77 billion by 2030. The Intrauterine Devices market is witnessing a positive market growth owing to the factors such as, increasing awareness about family planning, high rates of unintended pregnancies which pay way for increased tendency for planned or delayed pregnancies, various healthcare initiatives by government around contraception, are all contributing to the growth of the Intrauterine Devices Market during the forecast period from 2024-2030.

Intrauterine Devices Market Dynamics:

One of the main drivers of the Intrauterine Devices (IUDs) market is the increasing awareness about family planning. In November 2020, World Health Organization (WHO) released worldwide data on contraceptive methods that in 2019, 1.1 billion women of reproductive age (15-49) need family planning, of whom 842 million use contraceptive methods, and 270 million have unmet need for contraception.

Family planning is a choice of most of the parents these days which demand the need of contraceptives to delay pregnancies or limit the number of children, since IUDs are better than other contraceptives methods as they are 99% effective and provide long term protection against pregnancy. Therefore, increase in contraceptive demand will increase the demand of IUDs, thereby propelling the growth of the intrauterine devices market in the forecast period (2024-2030).

Moreover, another key factor that may be responsible for the rise in intrauterine devices market is high rates of unintended pregnancies. Around the globe in low and middle income countries, 74 million women have unintended pregnancies annually resulting in 25 million abortions and 47000 maternal deaths each year.

Additionally, according to the WHO in November 2022, worldwide approximately 6 in 10 unintended pregnancies results in induced abortion from which 45% of abortions are unsafe, can lead to death of mother. Worldwide each year approximately 73 million induced abortions takes place. Each year 4.7-13.2% maternal deaths takes place due to unsafe abortions, nearly 220 maternal death per 100,000 happens in developing region. Therefore, to overcome maternal deaths, contraceptives such as IUDs should be used which can reduce unintended pregnancies.

Thus, the use of IUDs can help women for family planning concerns to prevent unintended pregnancies, unsafe abortions and maternal deaths. Therefore, because of the above mentioned factors, an increase in IUD market will be seen in forecast period.

However, intrauterine devices can cause serious health issues such as infection, bleeding, pain, among others moreover, it does not protect against Sexually Transmitted Diseases (STDs), thus this become challenging which can slow down the intrauterine devices market growth.

COVID-19 pandemic has impacted the market for intrauterine devices. Lockdown restrictions in many countries confined people to be at their homes. Hence, birth controls, sexual and reproductive needs were out of their reach due to which unwanted pregnancies increased. However, with masses being vaccinated, the intrauterine devices market has picked momentum and is expected to grow during the forecast period.

Intrauterine Devices Market Segment Analysis:

Intrauterine Devices Market By Type (Hormonal Intrauterine and Copper Intrauterine), By End-User Type (Hospitals, Gynecology Clinics and Community Health Care Centers), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the by type segment of IUDs market, the hormonal intrauterine are estimated to hold the highest market share during the forecast period (2024-2030).

According to family planning NSW, both hormonal IUDs and copper IUDs are very effective, more than 99%. However, hormonal IUDs are found to be 99.8% effective and copper IUDs are 99.2% effective which means hormonal IUDs are more effective than copper IUDs.

Therefore, hormonal IUDs are preferred more because it contains hormone which helps to reduce period pain as well as bleeding while copper IUDs can make heavier periods and can cause cramps.

In August 2022, Bayer announced that US Food and Drug Administration (FDA) has approved Supplemental New Drug application (sNDA) to extend the life span of Mirena IUD.

In October 2019, FDA approved Medicines360's LILETTA, alevonorgestrel-releasing intrauterine system 52 mg which can prevent pregnancy for up to six years.

In May 2018, Medicines360 announced the launch of its hormonal IUD Avibela in Madagascar.

Furthermore, factors such as reduce in period pain and bleeding, supports the hormonal IUDs demand thereby will drive the growth of overall intrauterine devices market during the forecast period from 2024-2030.

North America is expected to dominate the overall Intrauterine Devices:

Among all the regions, North America is expected to account for the largest share in the global intrauterine devices, increased tendency for planned or delayed pregnancies, and government initiatives towards family planning awareness, are all contributing to the growth of the intrauterine devices market in the region.

Tendency of planned pregnancies have increased due to increasing female employment, additional education of women and medical reasons can be the factors responsible for planned/delayed pregnancies. Therefore, use of contraceptive methods such as IUDs can be preferred to delay pregnancies, they are safe, effective and long lasting methods, and increase in IUDs demand in turn would provide a conducive growth environment for North American region IUDs market growth.

Moreover, governmental initiatives such as in October 2020, Pan American Health Organization (PAHO) in collaboration with United Nations Population Fund (UNPFA) and WHO, conducted an adolescent pregnancy prevention week from 18th October - 24th October 2020. They hosted webinar, technical meeting on adolescent pregnancy prevention and risks related to it in Caribbean.

Thus, factors such as planned delayed pregnancies and healthcare initiatives by government help people to understand the risks related to unintended pregnancies and advantages of family planning which also results in population growth control. These programmes make people aware about use of contraceptives therefore, increasing the demand of IUDs which in turn would provide a conducive growth environment for North American region intrauterine devices market.

Intrauterine Devices Market Key Players:

Some of the key market players operating in the intrauterine devices market include CooperSurgical Inc, Bayer AG, Odyssea Pharma SPRL, Merck & Co Inc, Allergan Inc, EUROGINE S.L, OCON Medical Ltd, HLL Lifecare Limited, Mona Lisa, Prosan International BV, SMB Corporation of India, Medicines360, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Pregna International Limited, HRA Pharma, Melbea Innovations, Mylan N.V, Meril Life Sciences Pvt. Ltd, among others.

Recent Developmental Activities in the Intrauterine Devices:

• In October 2022, Bayer announced to invest Euro 400 million to expand access to modern contraception.
• In December 2020, to assist the US launch of Intrauterine Ball (IUB), Ballerine Rhia Ventures invested in Israeli based OCON Healthcare.
• In August 2022, launch of Avibela hormonal intrauterine device in Kenya was announced by Medicines360, MSI Reproductive Choices and MSK.

Key Takeaways from the Intrauterine Devices Market Report Study

• Market size analysis for current Intrauterine Devices Market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Intrauterine Devices.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global Intrauterine Devices.
• Various opportunities available for the other competitor in the Intrauterine Devices Market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current Intrauterine Devices Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Intrauterine Devices Market growth in the coming future?

Target Audience who can be benefited from this Intrauterine Devices Market Report Study

• Intrauterine Devices products providers
• Research organizations and consulting companies
• Intrauterine Devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Elastomeric Pumps
• Various End-users who want to know more about the Intrauterine Devices Market and latest technological developments in the Intrauterine Devices.

Frequently Asked Questions for Intrauterine Devices:

1. What are Intrauterine Devices?

Intrauterine Devices are small devices which are inserted inside the womb (uterus) of women by doctors to prevent pregnancies, which give protection against pregnancy for 5-10 years. These are one form of long-acting reversible birth control.

2. What is the market for Global Intrauterine Devices?

Global Intrauterine Devices Market was valued at USD 4.85 billion in 2023, growing at a CAGR of 5.81% during the forecast period from 2024 to 2030 to reach USD 6.77 billion by 2030.

3. What are the drivers for the Global Intrauterine Devices Market?

The Intrauterine Devices market is witnessing a positive market growth owing to the factors such as, family planning, increased tendency for planned delayed pregnancies, high rates of unintended pregnancies, , and healthcare initiatives by government.

4. Who are the key players operating in the Intrauterine Devices Market?

Some of the key market players operating in the Intrauterine Devices Market include CooperSurgical Inc, Bayer AG, Odyssea Pharma SPRL, Merck & Co Inc, Allergan Inc, EUROGINE S.L, OCON Medical Ltd, HLL Lifecare Limited, Mona Lisa, Prosan International BV, SMB Corporation of India, Medicines360, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Pregna International Limited, HRA Pharma, Melbea Innovations, Mylan N.V, Meril Life Sciences Pvt. Ltd, among others.

5. Which region has the highest share in Intrauterine Devices Market?

North America is expected to hold the highest share in the revenue of intrauterine devices market during the forecast period. High abortion rates, healthcare initiatives by government for family planning and to prevent unintended pregnancies will increase the demand for intrauterine devices in North America leading to a rise in the overall intrauterine devices market growth in this region.

Table of Contents

1.Intrauterine Devices Market Report Introduction

2.Intrauterine Devices Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The US
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Intrauterine Devices Market Key Factors Analysis

• 4.1. Intrauterine Devices Market Drivers
  • 4.1.1. High rates of unintended pregnancies
  • 4.1.2. Awareness about Family Planning
  • 4.1.3. Increased Tendency For Planned/Delayed Pregnancies
  • 4.1.4. Healthcare Initiatives By Government
• 4.2. Intrauterine Devices Market Restraints and Challenges
  • 4.2.1. IUDs Can Cause Serious Health Issues
  • 4.2.2. IUDs Does Not Give Protection Against STDs
• 4.3. Intrauterine Devices Market Opportunities
  • 4.3.1. Increasing Research and Development Activities in Intrauterine Devices
  • 4.3.2. Contraceptive Awareness Programs

5. Intrauterine Devices Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Intrauterine Devices

7. Intrauterine Devices Market Layout

• 7.1. By Product Type
  • 7.1.1. Hormonal Intrauterine
  • 7.1.2. Copper Intrauterine
• 7.2. By End User Type
  • 7.2.1. Hospitals
  • 7.2.2. Gynecology Clinics
  • 7.2.3. Community Health Care Centers
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. North America Intrauterine Devices Market, by Country
    • 7.3.1.1.1. US
    • 7.3.1.1.2. Canada
    • 7.3.1.1.3. Mexico
  • 7.3.2. Europe
    • 7.3.2.1. Europe Intrauterine Devices Market, by Country
    • 7.3.2.1.1. France
    • 7.3.2.1.2. Germany
    • 7.3.2.1.3. United Kingdom
    • 7.3.2.1.4. Italy
    • 7.3.2.1.5. Spain
    • 7.3.2.1.6. Russia
    • 7.3.2.1.7. Rest of Europe
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. Asia-Pacific Intrauterine Devices Market, by Country
    • 7.3.3.1.1. China
    • 7.3.3.1.2. Japan
    • 7.3.3.1.3. India
    • 7.3.3.1.4. Australia
    • 7.3.3.1.5. South Korea
    • 7.3.3.1.6. Rest of Asia Pacific
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. RoW Intrauterine Devices Market, by Region
    • 7.3.4.1.1. Middle East
    • 7.3.4.1.2. Africa
    • 7.3.4.1.3. South America

8. Intrauterine Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Intrauterine Devices Market Company and Product Profiles

• 9.1. CooperSurgical Inc
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Bayer AG
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Odyssea Pharma SPRL
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Merck & Co Inc
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Allergan Inc
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. EUROGINE S.L
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. OCON Medical Ltd
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. HLL Lifecare Limited
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Mona Lisa
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Prosan International BV
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. SMB Corporation of India
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Medicines360
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. AbbVie Inc
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Teva Pharmaceutical Industries Ltd
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Pregna International Limited
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. HRA Pharma
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Melbea Innovations
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Mylan N.V
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Meril Life Sciences Pvt. Ltd
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us